AIMC Topic: Drug Therapy, Combination

Clear Filters Showing 31 to 40 of 62 articles

Synergism of prenylflavonoids from Morus alba root bark against clinical MRSA isolates.

Phytomedicine : international journal of phytotherapy and phytopharmacology
BACKGROUND: Clinical methicillin-resistant Staphylococcus aureus (MRSA) is a thorny problem in current anti-infective therapeutics and a challenge of new drug development. Plant prenylflavonoids possess anti-MRSA activity, but few of the prenylflavon...

Optimal treatment assignment to maximize expected outcome with multiple treatments.

Biometrics
When there is substantial heterogeneity of treatment effectiveness, it is crucial to identify individualized treatment assignment rules for comparative treatment selection. Traditional approaches directly model clinical outcome and define optimal tre...

Continuous Adaptive Population Reduction (CAPR) for Differential Evolution Optimization.

SLAS technology
Differential evolution (DE) has been applied extensively in drug combination optimization studies in the past decade. It allows for identification of desired drug combinations with minimal experimental effort. This article proposes an adaptive popula...

Adequate tacrolimus concentration for myasthenia gravis treatment.

European journal of neurology
BACKGROUND AND PURPOSE: A single, oral dose of 3 mg/day tacrolimus, approved for myasthenia gravis (MG) treatment in Japan, was shown to reduce steroid dose and anti-acetylcholine receptor (AChR) antibody titers as well as to improve MG symptoms. How...

Impact of renal impairment on platelet reactivity and clinical outcomes during chronic dual antiplatelet therapy following coronary stenting.

European heart journal. Cardiovascular pharmacotherapy
AIMS: Clinical utilization of dual antiplatelet therapy (DAPT) in patients with renal impairment (RI) following percutaneous coronary interventions (PCI) represents an urgent, unmet need choosing optimal agents, duration of treatment, and potential d...